Scholarlink

Background <p>This scoping review synthesized evidence on vitamin D, parathyroid hormone (PTH), and serum calcium in bipolar disorder (BD) to evaluate their potential clinical utility.</p> Methods <p>A systematic PubMed search identified original studies examining calcium metabolism biomarkers (vitamin D, PTH, serum calcium) exclusively in BD populations. Findings were synthesized narratively due to substantial methodological heterogeneity.</p> Results <p>Fourteen studies met inclusion criteria, with small sample sizes (median <i>n</i> = 55) and predominantly cross-sectional designs. Vitamin D comparisons between BD patients and controls yielded contradictory results: three studies reported significantly lower levels in BD patients, two found significantly higher levels, and three found no differences. Vitamin D deficiency definitions varied widely (&lt; 25 to &lt; 50 nmol/L), precluding meaningful comparisons. Four cognition studies showed inconsistent associations with vitamin D, with negative correlations, age-dependent effects, or no associations reported. Two small vitamin D supplementation studies in bipolar spectrum disorders yielded contradictory results in distinct populations, with one in youth and the other in adults. Data on PTH and calcium were sparse and inconsistent.</p> Limitations <p>Study limitations included a single database search, substantial study heterogeneity, and inadequate control for confounders, including seasonal variation.</p> Conclusions <p>Evidence on calcium metabolism biomarkers in BD is contradictory and methodologically limited. Fundamental inconsistencies in vitamin D status between BD patients and controls, combined with conflicting supplementation data, preclude clinical recommendations. Routine vitamin D screening specifically for BD management cannot be supported. Large-scale, standardized studies are needed before clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vitamin D and calcium metabolism in bipolar disorder: a scoping review of contradictory evidence

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月25日

查看全文
  • Amirzhan Kulmagambetov,
  • Adelina Tmava-Berisha,
  • Frederike T. Fellendorf,
  • Melanie Lenger,
  • Tatjana Stross,
  • Marko Stijic,
  • Eva Fleischmann,
  • Julia Ilić,
  • Alexander Finner,
  • Anna Ramirez-Obermayer,
  • Johanna Georgi,
  • Alexander Maget,
  • Amrei Lässer,
  • Claudia Mittmannsgruber,
  • Stefan Smolle,
  • Alfred Häussl,
  • Jonas Schuller,
  • Dino Hasic,
  • Susanne Bengesser,
  • Robert Queissner,
  • Nina Dalkner,
  • Eva Z. Reininghaus

摘要

Background

This scoping review synthesized evidence on vitamin D, parathyroid hormone (PTH), and serum calcium in bipolar disorder (BD) to evaluate their potential clinical utility.

Methods

A systematic PubMed search identified original studies examining calcium metabolism biomarkers (vitamin D, PTH, serum calcium) exclusively in BD populations. Findings were synthesized narratively due to substantial methodological heterogeneity.

Results

Fourteen studies met inclusion criteria, with small sample sizes (median n = 55) and predominantly cross-sectional designs. Vitamin D comparisons between BD patients and controls yielded contradictory results: three studies reported significantly lower levels in BD patients, two found significantly higher levels, and three found no differences. Vitamin D deficiency definitions varied widely (< 25 to < 50 nmol/L), precluding meaningful comparisons. Four cognition studies showed inconsistent associations with vitamin D, with negative correlations, age-dependent effects, or no associations reported. Two small vitamin D supplementation studies in bipolar spectrum disorders yielded contradictory results in distinct populations, with one in youth and the other in adults. Data on PTH and calcium were sparse and inconsistent.

Limitations

Study limitations included a single database search, substantial study heterogeneity, and inadequate control for confounders, including seasonal variation.

Conclusions

Evidence on calcium metabolism biomarkers in BD is contradictory and methodologically limited. Fundamental inconsistencies in vitamin D status between BD patients and controls, combined with conflicting supplementation data, preclude clinical recommendations. Routine vitamin D screening specifically for BD management cannot be supported. Large-scale, standardized studies are needed before clinical application.